Last reviewed · How we verify

DISC-1459 — Competitive Intelligence Brief

DISC-1459 (DISC-1459) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepcidin mimetic. Area: Hematology.

phase 3 Hepcidin mimetic Ferroportin (iron exporter); hepcidin pathway agonist Hematology Small molecule Live · refreshed every 30 min

Target snapshot

DISC-1459 (DISC-1459) — Disc Medicine, Inc. DISC-1459 is a hepcidin mimetic that increases hepcidin levels to reduce iron absorption and circulating iron, thereby treating iron overload disorders.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DISC-1459 TARGET DISC-1459 Disc Medicine, Inc phase 3 Hepcidin mimetic Ferroportin (iron exporter); hepcidin pathway agonist

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepcidin mimetic class)

  1. Disc Medicine, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DISC-1459 — Competitive Intelligence Brief. https://druglandscape.com/ci/disc-1459. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: